EGYPTIAN INTERNATIONAL PHARMACEUTICALS (EIPICO) financial statements, including revenue, expenses, profit, and loss

The total revenue of PHAR for the last quarter is 1.55 B EGP, and it's 21.37% higher compared to the previous quarter. The net income of Q4 23 is 179.21 M EGP.